NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.

NICE has rejected Roche's breast cancer treatment Kadcyla for a second time, saying its benefits do not justify its price, even after a discount from the manufacturer. The decision has been called ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...